Actively Recruiting
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-05-01
36
Participants Needed
2
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
CONDITIONS
Official Title
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Diagnosed with advanced hepatocellular carcinoma (HCC) confirmed by histopathology, cytology, or clinical diagnosis
- Barcelona clinical liver cancer stage B or C
- No prior systemic antitumor therapy for HCC
- At least one measurable lesion according to RECIST v1.1 criteria
- Child-Pugh score of A or B7
- ECOG performance status of 0 or 1
- Expected survival time of at least 12 weeks
- Well-functioning major organs
- Signed informed consent form
You will not qualify if you...
- Hepatobiliary cell carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma
- Active malignant tumors other than HCC within 5 years or simultaneously, except certain localized tumors that have been cured
- Previous allogeneic organ transplantation such as liver transplantation
- Liver tumor burden greater than 50% of total liver volume
- CTCAE grade 3 bleeding within 6 months or grade 2 nongastrointestinal bleeding within 3 months before first dose
- Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before first dose
- Major vascular disease within 6 months before first dose
- Current or previous interstitial pneumonia or interstitial lung disease requiring hormone therapy
- Innate or acquired immune deficiency such as HIV infection
- Severe infection within 28 days before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350002
Actively Recruiting
2
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530021
Actively Recruiting
Research Team
Y
Yang Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here